Bacainn Therapeutics Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
Bacainn Therapeutics General Information
Description
Developer of novel cell therapies designed to address uncontrolled inflammation driven by dysregulated immune cells. The company's therapies are focused on the discovery and development of novel immune cell-modulating drugs to control ulcerative colitis, diabetic wound healing, respiratory inflammation, and oncology, enabling medical professionals to investigate the use of these drugs and to bring damaging inflammation under control.
Contact Information
Website
bacainntherapeutics.comCorporate Office
- 530 Virginia Road
- Suite 300
- Concord, MA 01742
- United States
Corporate Office
- 530 Virginia Road
- Suite 300
- Concord, MA 01742
- United States
Bacainn Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 10-Mar-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC | Completed | Startup |
Bacainn Therapeutics Patents
Bacainn Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4611734-A1 | Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions | Pending | 04-Nov-2022 | ||
| US-20260176232-A1 | Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions | Pending | 04-Nov-2022 | ||
| US-20240277798-A1 | Cyclosporine compositions and methods of use | Pending | 20-Apr-2021 | ||
| AU-2021303146-A1 | Probenecid compounds for the treatment of inflammasome-mediated lung disease | Pending | 29-Jun-2020 | ||
| CA-3184151-A1 | Probenecid compounds for the treatment of inflammasome-mediated lung disease | Pending | 29-Jun-2020 | C07D211/34 |
Bacainn Therapeutics Signals
Bacainn Therapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Morningside Group | Venture Capital | Minority |
Bacainn Therapeutics Acquisitions (1)
Bacainn Therapeutics’s most recent deal was a Merger of Equals with Adiso Therapeutics. The deal was made on 10-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Adiso Therapeutics | 10-Mar-2022 | Merger of Equals | Drug Discovery |
Bacainn Therapeutics FAQs
-
When was Bacainn Therapeutics founded?
Bacainn Therapeutics was founded in 2017.
-
Where is Bacainn Therapeutics headquartered?
Bacainn Therapeutics is headquartered in Concord, MA.
-
What is the size of Bacainn Therapeutics?
Bacainn Therapeutics has 9 total employees.
-
What industry is Bacainn Therapeutics in?
Bacainn Therapeutics’s primary industry is Drug Discovery.
-
Is Bacainn Therapeutics a private or public company?
Bacainn Therapeutics is a Private company.
-
What is Bacainn Therapeutics’s current revenue?
The current revenue for Bacainn Therapeutics is .
-
Who are Bacainn Therapeutics’s investors?
Morningside Group has invested in Bacainn Therapeutics.
-
When was Bacainn Therapeutics acquired?
Bacainn Therapeutics was acquired on 10-Mar-2022.
-
Who acquired Bacainn Therapeutics?
Bacainn Therapeutics was acquired by Adiso Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process